Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Please consult a physician for specific treatment recommendations.
Fluorescence emission readings were analyzed using Rotor-Gene Q software (Qiagen, Germany)
T.MajumdarS
Opiorphin and kallikrein-kinin peptides act on semen quality and motility
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
This combination therapy demonstrated potential to improve key semen parameters, particularly forward motility and total motile sperm counts, while also contributing to enhanced pregnancy rates in affected patients (73)
US$ 26.41
US$ 28.36
US$ 23.29
US$ 27.61
US$ 20.71
US$ 29.06
US$ 26.41
US$ 24.20
US$ 27.42
US$ 26.75
US$ 23.60
US$ 24.44